Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $7.07 and last traded at $7.10, with a volume of 78892 shares changing hands. The stock had previously closed at $7.32.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. Scotiabank dropped their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, Bank of America reduced their price objective on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.38.
View Our Latest Report on KURA
Kura Oncology Trading Down 3.6 %
Institutional Investors Weigh In On Kura Oncology
Several institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC bought a new stake in shares of Kura Oncology during the 3rd quarter valued at about $25,000. The Manufacturers Life Insurance Company raised its stake in Kura Oncology by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after buying an additional 1,976 shares during the period. Harbor Capital Advisors Inc. raised its stake in Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after buying an additional 2,076 shares during the period. Hsbc Holdings PLC raised its stake in Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after buying an additional 2,167 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock worth $7,997,000 after buying an additional 3,092 shares during the period.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Further Reading
- Five stocks we like better than Kura Oncology
- Short Selling: How to Short a Stock
- Delta Can Fly to New Highs in 2025; Here’s Why
- ETF Screener: Uses and Step-by-Step Guide
- Snowflake Stock: Bullish Upgrades Demand Investors’ Attention
- How to Calculate Return on Investment (ROI)
- 3 Dividend Stocks With Growth Potential You Can’t Miss
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.